» Articles » PMID: 12807877

Expression of Mutant Huntingtin Blocks Exocytosis in PC12 Cells by Depletion of Complexin II

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Jun 17
PMID 12807877
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat in the HD gene. We reported recently that complexin II, a protein involved in neurotransmitter release, is depleted from both the brains of mice carrying the HD mutation and from the striatum of post mortem HD brains. Here we show that this loss of complexin II is recapitulated in PC12 cells expressing the HD mutation and is accompanied by a dramatic decline in Ca2+-triggered exocytosis of neurotransmitter. Overexpression of complexin II (but not complexin I) rescued exocytosis, demonstrating that the decline in neurotransmitter release is a direct consequence of complexin II depletion. Complexin II depletion in the brain may account for some of the abnormalities in neurotransmission associated with HD.

Citing Articles

Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington's Disease.

Pradhan S, Gao R, Bush K, Zhang N, Wairkar Y, Sarkar P Front Cell Neurosci. 2022; 16:837576.

PMID: 35444517 PMC: 9013776. DOI: 10.3389/fncel.2022.837576.


Huntingtin and the Synapse.

Barron J, Hurley E, Parsons M Front Cell Neurosci. 2021; 15:689332.

PMID: 34211373 PMC: 8239291. DOI: 10.3389/fncel.2021.689332.


Cortical Axonal Secretion of BDNF in the Striatum Is Disrupted in the Mutant-huntingtin Knock-in Mouse Model of Huntington's Disease.

Park H Exp Neurobiol. 2018; 27(3):217-225.

PMID: 30022873 PMC: 6050413. DOI: 10.5607/en.2018.27.3.217.


Huntington's Disease and Diabetes: Chronological Sequence of its Association.

Montojo M, Aganzo M, Gonzalez N J Huntingtons Dis. 2017; 6(3):179-188.

PMID: 28968242 PMC: 5676851. DOI: 10.3233/JHD-170253.


Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Li Y, Kavalali E Pharmacol Rev. 2017; 69(2):141-160.

PMID: 28265000 PMC: 5394918. DOI: 10.1124/pr.116.013342.